Figure 4.

Comparison of imaging findings between 2 patients treated with apatinib for stage IV osteogenic sarcoma that did not respond to chemotherapy. (A-F) Efficacy in patients who were diagnosed with stage IV osteosarcoma at the first visit and received apatinib after they did not respond to first-line chemotherapy. (A, C, E) Imaging findings before treatment with apatinib (January 23, 2017). (B, D, F) Positron emission tomography-CT showed significant decreases in the sizes and metabolic activity of the tumors after treatment with apatinib (April 10, 2017). (G-H) Effects of apatinib in patients with metastatic Ewing’s sarcoma in the lungs who did not respond to first-line chemotherapy. (G) CT images of the chest before treatment with apatinib (May 25, 2017). (H) The lesions in the lungs remained stable from initiation of oral use of apatinib on May 25, 2017 to re-examination on November 24, 2017.